The epidermal growth factor receptor (EGFR) signaling pathway attained considerable importance a few years ago as a therapeutic target in NSCLC.6 Tyrosine kinase inhibitors (TKIs) that control the EGFR are very efficacious in EGFR mutation treatment with a characteristic therapeutic window. This evidence concerns the gene EGFR and non-small cell lung carcinoma.